304 related articles for article (PubMed ID: 32838660)
1. Structure-based drug repurposing for targeting Nsp9 replicase and spike proteins of severe acute respiratory syndrome coronavirus 2.
Chandel V; Sharma PP; Raj S; Choudhari R; Rathi B; Kumar D
J Biomol Struct Dyn; 2022 Jan; 40(1):249-262. PubMed ID: 32838660
[TBL] [Abstract][Full Text] [Related]
2. Multi-targeting approach for nsp3, nsp9, nsp12 and nsp15 proteins of SARS-CoV-2 by Diosmin as illustrated by molecular docking and molecular dynamics simulation methodologies.
Kumar S; Sharma PP; Upadhyay C; Kempaiah P; Rathi B; Poonam
Methods; 2021 Nov; 195():44-56. PubMed ID: 33639316
[TBL] [Abstract][Full Text] [Related]
3. Addressing the potential role of curcumin in the prevention of COVID-19 by targeting the Nsp9 replicase protein through molecular docking.
Kumar M; Sodhi KK; Singh DK
Arch Microbiol; 2021 May; 203(4):1691-1696. PubMed ID: 33459817
[TBL] [Abstract][Full Text] [Related]
4. Virtual screening of phytochemicals by targeting multiple proteins of severe acute respiratory syndrome coronavirus 2: Molecular docking and molecular dynamics simulation studies.
Azeem M; Mustafa G; Mahrosh HS
Int J Immunopathol Pharmacol; 2022; 36():3946320221142793. PubMed ID: 36442514
[TBL] [Abstract][Full Text] [Related]
5. Exploring potential inhibitor of SARS-CoV2 replicase from FDA approved drugs using insilico drug discovery methods.
Chandra A; Gurjar V; Ahmed MZ; Alqahtani AS; Qamar I; Singh N
J Biomol Struct Dyn; 2022 Aug; 40(12):5507-5514. PubMed ID: 33491573
[TBL] [Abstract][Full Text] [Related]
6. Silybin B and Cianidanol Inhibit M
Srivastava R; Tripathi S; Unni S; Hussain A; Haque S; Dasgupta N; Singh V; Mishra BN
Curr Pharm Des; 2021; 27(32):3476-3489. PubMed ID: 33302853
[TBL] [Abstract][Full Text] [Related]
7. Computational repurposing approach for targeting the critical spike mutations in B.1.617.2 (delta), AY.1 (delta plus) and C.37 (lambda) SARS-CoV-2 variants using exhaustive structure-based virtual screening, molecular dynamic simulations and MM-PBSA methods.
Ebrahimi M; Karami L; Alijanianzadeh M
Comput Biol Med; 2022 Aug; 147():105709. PubMed ID: 35728285
[TBL] [Abstract][Full Text] [Related]
8. Repurposing potential of FDA-approved and investigational drugs for COVID-19 targeting SARS-CoV-2 spike and main protease and validation by machine learning algorithm.
Verma AK; Aggarwal R
Chem Biol Drug Des; 2021 Apr; 97(4):836-853. PubMed ID: 33289334
[TBL] [Abstract][Full Text] [Related]
9. Drug repurposing against SARS-CoV-2 receptor binding domain using ensemble-based virtual screening and molecular dynamics simulations.
Kumar V; Liu H; Wu C
Comput Biol Med; 2021 Aug; 135():104634. PubMed ID: 34256255
[TBL] [Abstract][Full Text] [Related]
10. In silico prediction of potential inhibitors for the main protease of SARS-CoV-2 using molecular docking and dynamics simulation based drug-repurposing.
Kumar Y; Singh H; Patel CN
J Infect Public Health; 2020 Sep; 13(9):1210-1223. PubMed ID: 32561274
[TBL] [Abstract][Full Text] [Related]
11. In-silico evaluation of natural alkaloids against the main protease and spike glycoprotein as potential therapeutic agents for SARS-CoV-2.
Shah M; Yamin R; Ahmad I; Wu G; Jahangir Z; Shamim A; Nawaz H; Nishan U; Ullah R; Ali EA; Sheheryar ; Chen K
PLoS One; 2024; 19(1):e0294769. PubMed ID: 38175855
[TBL] [Abstract][Full Text] [Related]
12. Computational screening of dual inhibitors from FDA approved antiviral drugs on SARS-CoV-2 spike protein and the main protease using molecular docking approach.
Sabarimurugan S; Purushothaman I; Swaminathan R; Dharmarajan A; Warrier S; Kothandan S
Acta Virol; 2021; 65(2):160-172. PubMed ID: 34130467
[TBL] [Abstract][Full Text] [Related]
13. Computational drug repurposing study of antiviral drugs against main protease, RNA polymerase, and spike proteins of SARS-CoV-2 using molecular docking method.
Jalalvand A; Khatouni SB; Najafi ZB; Fatahinia F; Ismailzadeh N; Farahmand B
J Basic Clin Physiol Pharmacol; 2021 Jul; 33(1):85-95. PubMed ID: 34265888
[TBL] [Abstract][Full Text] [Related]
14. Drug repurposing: identification of SARS-CoV-2 potential inhibitors by virtual screening and pharmacokinetics strategies.
Rashid Z; Fatima A; Khan A; Matthew J; Yousaf MZ; Nadeem N; Hasan TN; Rehman MU; Naqvi SS; Khan SJ
J Infect Dev Ctries; 2024 Apr; 18(4):520-531. PubMed ID: 38728643
[TBL] [Abstract][Full Text] [Related]
15. Structure based Drug Designing Approaches in SARS-CoV-2 Spike Inhibitor Design.
Shanmugam A; Venkattappan A; Gromiha MM
Curr Top Med Chem; 2022; 22(29):2396-2409. PubMed ID: 36330617
[TBL] [Abstract][Full Text] [Related]
16. Molecular screening of antimalarial, antiviral, anti-inflammatory and HIV protease inhibitors against spike glycoprotein of coronavirus.
Prashantha CN; Gouthami K; Lavanya L; Bhavanam S; Jakhar A; Shakthiraju RG; Suraj V; Sahana KV; Sujana HS; Guruprasad NM; Ramachandra R
J Mol Graph Model; 2021 Jan; 102():107769. PubMed ID: 33152616
[TBL] [Abstract][Full Text] [Related]
17. Discovery of Potent SARS-CoV-2 Inhibitors from Approved Antiviral Drugs via Docking and Virtual Screening.
Chtita S; Belhassan A; Aouidate A; Belaidi S; Bouachrine M; Lakhlifi T
Comb Chem High Throughput Screen; 2021; 24(3):441-454. PubMed ID: 32748740
[TBL] [Abstract][Full Text] [Related]
18. A natural product compound inhibits coronaviral replication in vitro by binding to the conserved Nsp9 SARS-CoV-2 protein.
Littler DR; Liu M; McAuley JL; Lowery SA; Illing PT; Gully BS; Purcell AW; Chandrashekaran IR; Perlman S; Purcell DFJ; Quinn RJ; Rossjohn J
J Biol Chem; 2021 Dec; 297(6):101362. PubMed ID: 34756886
[TBL] [Abstract][Full Text] [Related]
19. Design of novel viral attachment inhibitors of the spike glycoprotein (S) of severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) through virtual screening and dynamics.
Oany AR; Mia M; Pervin T; Junaid M; Hosen SMZ; Moni MA
Int J Antimicrob Agents; 2020 Dec; 56(6):106177. PubMed ID: 32987103
[TBL] [Abstract][Full Text] [Related]
20. Antiviral Efficacy of Selected Natural Phytochemicals against SARS-CoV-2 Spike Glycoprotein Using Structure-Based Drug Designing.
Aloufi BH; Snoussi M; Sulieman AME
Molecules; 2022 Apr; 27(8):. PubMed ID: 35458599
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
